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Plans to Implement a  
Statewide Integrated  
Screening Program in Iowa
A recent American College of Obstetricians and Gy-
necologists Practice Bulletin  (1) has spurred renewed 
interest  in  offering patients more  recently developed 
options to screen for fetal chromosome abnormalities. 
These  options  include  first  trimester  screening  and 







HIV Testing in Pregnancy
In September 2006, the Centers for Disease Control 
and  Prevention  (CDC)  released Revised Recommenda-
tions for HIV Testing of Adults Adolescents, and Pregnant 
Women in Health-Care Settings. These new recommenda-
tions, which replace the CDC’s 1993 Recommendations 
for HIV Testing Services for Inpatients and Outpatients in 
Acute-Care Hospital Settings, advise routine HIV screen-
ing  of  adults,  adolescents,  and  pregnant  women  in 
health-care settings in the United States. The CDC also 
recommends reducing barriers to HIV testing. 
In  these  revised Recommendations,  the CDC  is  rec-
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the false positive rate (FPR) while maintaining a high 
detection rate (DR) for Down syndrome.
Two  prospective  studies  have  validated  the  effi-
cacy  of  integrated  screening.    One  study,  conducted 
in  the UK and Europe,  carries  the  acronym SURUSS 
(Serum,  Urine  and  Ultrasound  Screening  Study)  (2) 
and  the  other  study,  conducted  in  the US,  is  known 
as  the  FASTER  (First  and  Second  Trimester  Evalua-
tion of Risk) trial (3).  Both of these studies combined 
first trimester screening, consisting of one ultrasound 





An  integrated  screening  proposal  has  been  ap-
proved  by  the  Center  for  Congenital  and  Inherited 
Disorders  Advisory  Committee  (formerly  the  Birth 
Defects  Institute Advisory  Committee),  a  body  with 
diverse membership  under  the  auspices  of  the  State 
Health Department.   The primary advantage of  inte-
grated  screening,  as  stated,  is  the  significantly  lower 




invasive  testing.   Figure 1 depicts  the decreased FPR 
of integrated screening as compared to other screening 
options currently available.
Factors which have  influenced  the decision  of  the 
above referenced Advisory Committee to approve in-
tegrated  screening  include  the decreasing percentage 
of women who are electing to undergo amniocentesis 
in the state, suggesting they would favor a lower FPR. 
From approximately  1993  to  the present,  our patient 
referral  base  to  the Prenatal Diagnosis Clinic  at Uni-































one  in  the  second  trimester,  as  opposed  to  a  single 
integrated  risk.   Another  criticism of  fully  integrated 
screening is that patients may be unwilling to wait for 
the  integrated test result, preferring to  initially know 





ing,  several  tasks  remain.    The  University  Hygienic 
Laboratory is establishing medians for the first trimes-
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NT Triple Screen Quad Screen NT, PAPP-A, hCG PAPP-A, Quad NT, PAPP-A, Quad
(Serum Integrated) (Fully Integrated)
Figure 1. Variation in False Positive Rates for a Fixed 85% Down Syndrome Detection Rate. This graph shows the FPR on the vertical axis for a
fixed DR of 85%. The measurement of NT alone is associated with an unacceptably high FPR. The current optimal screening in the second
trimester, the Quad screen, has the same FPR and DR as the optimal first trimester screen (NT, PAPP-A, hCG). If a woman elects integrated
screening but does not have access to an NT measurement or this measurement is available but cannot be obtained for technical reasons, the
Serum Integrated Screen with PAPP-A in the first trimester and the Quad screen in the second trimester will still significantly decrease the FPR.
The optimal test is the Fully Integrated Screen with NT measurement in the first trimester (1.2% FPR).
Figure 1. Variati n in False Positive Rates for a Fix d 85% 


















ratory  aspects  of  integrated  screening,  a major  focus 










undergo NT measurement,  if  it  is  performed  the  so-
nographer will  be  required  to  have  taken  one  of  the 
courses  which  certify  competence  in  this  measure-
ment.   These courses are provided  in North America 
through the Society for Maternal-Fetal Medicine.  If a 
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•  No  additional  process  or  written  documenta-
tion of informed consent should be required for 
HIV tests beyond that for other routine prena-














HIV  status,  and  the  use  of  antiretroviral  therapy  by 
HIV-infected women during pregnancy and by infants 
after  birth.  The  decrease  in  pediatric AIDS  and HIV 
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The  IDPH  is  working  toward  incorporating  key 
components of the CDC’s recommendations into Iowa 





141A.4 TESTING AND EDUCATION
Pregnant Women  
a.  All pregnant women shall be tested for HIV in-
fection  as  part  of  the  routine  panel  of  prenatal 
tests. 
b.  A  pregnant  woman  shall  be  notified  that  HIV 
screening  is  recommended  for  all  prenatal  pa-
tients and that she will receive an HIV test as part 
of  the  routine panel of prenatal  tests unless  the 
woman objects (opt-out).
c.  If a pregnant woman declines  testing,  this deci-
sion  should  be  documented  in  the  medical  re-
cord.
d.  Information  about  HIV  prevention,  risk  reduc-
tion,  and  treatment  opportunities  to  reduce  the 
possible  transmission of HIV  to a  fetus shall be 
made available to all pregnant women.
141A. HIV-RELATED CONDITIONS— 
CONSENT, TESTING, AND REPORTING
If a person signs a general consent form for the perfor-
mance of medical tests or procedures, the signing of an ad-
ditional consent form for the specific purpose of consent-
ing to an HIV-related test is not required during the time 
in which the general consent form is in effect.  If a person 
has not signed a general consent form for the performance 
of medical tests and procedures or the consent form is no 
longer in effect, a health care provider shall obtain oral or 
written consent prior to performing an HIV-related test.  If 
an individual is unable to provide consent, the individual’s 
legal guardian may provide consent.  If the individual’s le-
gal guardian cannot be located or is unavailable, a health 
care provider may authorize the test when the test results 













like  the  IDPH to consider.   Feel  free  to direct  this  in-
quiry  to others who may have expertise  in  this area. 
Please direct your written responses to:
Randy Mayer
HIV/AIDS/Hepatitis Program Manager
Iowa Department of Public Health
Lucas State Office Building
321 East 12th
Des Moines, IA 50319-0075
rmayer@idph.state.ia.us
 
